TGM2 and ovarian cancer: Increased frequency of activated B cells expressing CD69 was also evident in the Tgm2 knockout mice and increased B cell activation has been associated with an anti-tumoral response and improved overall survival in several cancer types including breast, prostate, lung, pancreatic, and ovarian cancer (44).